These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9601353)

  • 1. RSV-IG (respigam).
    Snyder R
    Neonatal Netw; 1998 Apr; 17(3):63-5. PubMed ID: 9601353
    [No Abstract]   [Full Text] [Related]  

  • 2. RespiGam: an RSV immune globulin.
    Oertel MD
    Pediatr Nurs; 1996; 22(6):525-8. PubMed ID: 9087091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respigam for protection against RSV.
    Burke SM
    MCN Am J Matern Child Nurs; 1996; 21(5):258. PubMed ID: 8840776
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G; Logvinoff MM; Zegarra N; Allen L; Jesurun A; Levin G; Thida A
    Tex Med; 2000 May; 96(5):58-61. PubMed ID: 10843015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of respiratory syncytial virus infection in high risk infants.
    Prince AM; Jacobs RF
    J Ark Med Soc; 2001 Oct; 98(4):115-8. PubMed ID: 11594047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis of respiratory syncytial virus infection.
    Simoes EA
    Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis for severe respiratory syncytial virus disease.
    Kupecz D
    Nurse Pract; 1996 Sep; 21(9):116-8. PubMed ID: 8884798
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunoprophylaxis with RespiGam.
    Meissner HC; Rennels MB; Long SS; Pickering LK
    Pediatrics; 2004 Mar; 113(3 Pt 1):629. PubMed ID: 14993568
    [No Abstract]   [Full Text] [Related]  

  • 12. Respiratory syncytial virus PREVENT Study questions.
    Raju TN
    Pediatrics; 1997 Dec; 100(6):1044; author reply 1045. PubMed ID: 9411386
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory syncytial virus PREVENT Study questions.
    Dransfield D; Kessler D; McCarthy C
    Pediatrics; 1997 Dec; 100(6):1044-5. PubMed ID: 9411387
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respiratory syncytial virus PREVENT Study questions.
    Moler FW
    Pediatrics; 1997 Dec; 100(6):1043-4; author reply 1045. PubMed ID: 9411385
    [No Abstract]   [Full Text] [Related]  

  • 16. Palivizumab (Synagis) for prevention of RSV infection.
    Med Lett Drugs Ther; 1999 Jan; 41(1043):3-4. PubMed ID: 9924488
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient Information. What is respiratory syncytial virus (RSV)?
    RN; 2005 Dec; 68(12):49. PubMed ID: 16411555
    [No Abstract]   [Full Text] [Related]  

  • 18. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
    DeVincenzo JP; Hirsch RL; Fuentes RJ; Top FH
    Bone Marrow Transplant; 2000 Jan; 25(2):161-5. PubMed ID: 10673674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of RespiGam at a university teaching hospital.
    Veerman M; Reuman P; Burchfield D; Sherman J
    Pediatrics; 1997 Jul; 100(1):160-1. PubMed ID: 9229713
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.